Streetbeat News

Revenues

DT

Dynatrace (NYSE:DT) has seen a shift in analyst sentiment over the past three months, with a decrease in the average price target by 6.29% to $60.6. Analysts from firms like BMO Capital, TD Cowen, and JP Morgan have adjusted their ratings and price targets, reflecting a mix of lowered expectations and maintained outlooks. Despite the negative sentiment shift, Dynatrace's financial performance remains strong, with a 22.74% revenue growth rate and a market capitalization that, while below industry averages, indicates potential for growth. The company's net margin and ROE are below industry averages, suggesting areas for improvement.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 9:01 pm

BLMN

Six analysts have recently updated their ratings on Bloomin Brands (NASDAQ:BLMN), showing a mix of perspectives with an average 12-month price target of $28.83, down from $29.00. The company's financial performance indicates strong profitability and efficient asset management, despite a high debt-to-equity ratio and lower revenue growth compared to peers. Bloomin Brands operates popular dining brands and has a presence in the U.S., Brazil, South Korea, and through franchising in Asia.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 9:00 pm

NVRO

Nevro Corp (NYSE:NVRO) has been evaluated by 9 financial analysts over the past three months, showing a predominantly indifferent stance with 8 indifferent ratings, and 1 somewhat bearish. The 12-month price targets have seen a decrease, with an average target now at $14.89, down from $18.00, indicating a 17.28% decrease. Analysts from firms including Canaccord Genuity, Wells Fargo, and Piper Sandler have lowered their price targets, reflecting concerns over Nevro's market performance and financial health. Despite positive revenue growth of 2.05% as of December 31, 2023, Nevro's market capitalization and debt management pose challenges, with a high debt-to-equity ratio of 0.74.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 9:00 pm

MQ

Marqeta (NASDAQ:MQ) received mixed analyst ratings in the last quarter, with a total of 5 evaluations ranging from bullish to indifferent. The average 12-month price target is $7.7, down 3.75% from the previous $8.00, indicating a downward trend in expectations. Analysts from firms including Wedbush, Monness, Crespi, Hardt, Keefe, Bruyette & Woods, Truist Securities, and B of A Securities provided insights, with actions ranging from maintaining to raising their ratings and price targets. Marqeta's financial performance shows challenges, with a significant revenue decline of -41.7% over the last 3 months and below-average metrics in market capitalization, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 9:00 pm

HHH

Howard Hughes Corporation (HHH) maintains its full-year 2024 guidance, with Cash G&A expected between $80 million and $90 million, excluding costs from the Seaport Entertainment spinoff and non-cash stock compensation. Condo sales revenues are forecasted between $675 million and $725 million, driven by the completion of Victoria Place in Ward Village, which is fully pre-sold and expected to complete in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:57 pm

DVAX

Dynavax has reaffirmed its full-year 2024 financial guidance, expecting an increase in cash and equivalents year-over-year by December 31, 2024. The company anticipates HEPLISAV-B net product revenue to be between $265 million and $280 million, which includes about $3 million from ex-U.S. sales through a commercialization partnership in Germany. Additionally, the HEPLISAV-B gross margin is projected to be around 80%.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:56 pm

TKO

TKO has raised its 2024 revenue forecast to a range of $2.610 billion to $2.685 billion, compared to the previous estimate of $2.66 billion.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:54 pm

IONQ

IonQ Inc (NYSE:IONQ) reported a 77% increase in Q1 revenue year-over-year to $7.582 million, surpassing the consensus estimate of $7.075 million. The company also reported a smaller-than-expected quarterly loss of 19 cents per share, beating analyst estimates for a loss of 24 cents per share. With $300,000 in new bookings and ending the quarter with $434.4 million in cash, equivalents, and investments, IonQ raised its full-year 2024 revenue and bookings guidance. The company's shares were up 3.2% after hours at $9.04.

Portfolio Pulse from Adam Eckert

May 08, 2024 | 8:50 pm

GNK

Genco Shipping & Trading (GNK) reported Q1 2024 earnings of $0.44 per share, missing the consensus estimate of $0.52. However, their sales of $117.20M exceeded the $90.74M estimate, marking a 24.16% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:49 pm

CPRX

Catalyst Pharmaceuticals has reaffirmed its FY24 total revenue guidance, projecting revenues to be in the range of $455M-$475M, aligning closely with the estimated $460.53M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:49 pm